Brigatinib/Brigatinib vs. Osimertinib: An in-depth comparison of two lung cancer drugs

Brigatinib and Osimertinib are two targeted therapies for different types of non-small cell lung cancer (NSCLC). Their main differences lie in the type of genetic mutation targeted and the corresponding treatment mechanism.

1. Drug positioning and genetic mutation

Brigatinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor specifically used to treat ALK-positive non-small cell lung cancer. Osimertinib is a third-generation oral irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It mainly targets non-small cell lung cancer with EGFR mutations, especially T790M mutations. The choice of these two drugs mainly depends on the specific genetic mutation type of the patient's lung cancer cells.

2. Mechanism of action and efficacy

Brigatinib was originally designed to overcome resistance to the first-generationALK inhibitor crizotinib. It has been shown to have significant efficacy in patients refractory to crizotinib and is being evaluated as a first-line treatment option. In patients with ALK-positive non-small cell lung cancer, brigatinib has shown high therapeutic effects in terms of progression-free survival (PFS) and objective response rate (ORR). In contrast, osimertinib has a particularly significant effect in patients with tumors carrying the EGFR T790M mutation. This mutation is a common mechanism of resistance to early EGFR inhibitors. Compared with standard first-line treatment of EGFR-mutated non-small cell lung cancer, osimertinib has a significant improvement in progression-free survival.

3. Clinical trial evidence

The efficacy of brigatinib was further verified in the ALTA-1L trial. This is a phase III study comparing brigatinib and crizotinib in patients with ALK-positive non-small cell lung cancer who have not received ALK inhibitor therapy. The study results showed that compared with crizotinib, brigatinib showed significant advantages in prolonging PFS. It is worth noting that brigatinib also demonstrated a high intracranial ORR in patients with brain metastases, which is undoubtedly an important therapeutic breakthrough for ALK-positive non-small cell lung cancer, a common complication.

The efficacy of osimertinib was confirmed in the FLAURA study. This is a pivotal Phase III clinical trial designed to compare osimertinib with standard EGFR-TKIs (such as erlotinib or gefitinib) in the first-line treatment of EGFR-mutated non-small cell lung cancer. The study results showed that osimertinib not only significantly prolonged PFS (median time was 18.9 months compared with 10.2 months in the control group), but was also closely associated with a higher objective response rate and longer duration of response.

In summary, brigatinib and osimertinib have their own merits in the treatment of non-small cell lung cancer. Their choice mainly depends on the patient's specific genetic mutation type and treatment needs. Therefore, when formulating treatment plans, doctors should make individualized drug selections based on the patient's specific conditions.